02521nam 22006373 450 991082994500332120220610194715.00-470-84635-697866105548811-280-55488-6(OCoLC)85820010(CKB)111056485557306(MiAaPQ)EBC4956309(Au-PeEL)EBL4956309(CaONFJC)MIL55488(OCoLC)1024259038(EXLCZ)9911105648555730620210901d2003 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierDrug resistance in epilepsy1st ed.New York :Wiley,2003.©2003.1 online resource (254 pages)Novartis Foundation Symposia ;v.Vol. 2430-470-84146-X 0-470-85189-9 The object of this book is to gather together workers in the fields of epilepsy, those concerned with the basic science of resistance and the blood-brain barrier, and those with clinical experience of drug resistance in cancer, with a view to stimulating further work on drug resistance in epilepsy. Whilst resistance in cancer has been extensively studied, and trials of reversal of resistance have been undertaken, with some success, resistance in epilepsy has only just begun to be addressed.Novartis Foundation SymposiaMechanisms of Drug Resistance in EpilepsyDrug Resistance in EpilepsyNovartis Foundation Symposium 243 - Mechanisms of Drug Resistance in Epilepsy - Lessons from OncologyEpilepsydrug therapyATP Binding Cassette Transporter, Subfamily BmetabolismDrug ResistanceCongress.Epilepsydrug therapy.ATP Binding Cassette Transporter, Subfamily Bmetabolism.Drug Resistance.616.853061Foundation Novartis1634236Bock Gregory322650Goode Jamie283336Novartis Foundation.Symposium on Mechanisms of Drug Resistance in Epilepsy : Lessons from Oncology(2001 :London, England)MiAaPQMiAaPQMiAaPQBOOK9910829945003321Drug resistance in epilepsy3974364UNINA